Press Releases and Blog
Blog
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
ICYMI: Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: “Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug
ICYMI: Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
ICYMI: JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper,
Current And Former Policymakers, Experts Agree Anti-PBM Bills Restrict Free Market, Would Do Nothing To Lower Rx Drug Costs
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers
Press Releases
PCMA Statement on House Ways and Means Committee and Senate Finance Committee Legislation
What Problem is Congress Trying to Solve? (Washington D.C.) – The Pharmaceutical Care Management Association released the following statement on today’s votes in the Senate
PCMA Statement on Federal Trade Commission Vote on PBM Advocacy
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote by the Federal Trade Commission (FTC): “We agree with
PCMA Statement On House Education And The Workforce Committee, Subcommittee On Health, Employment, Labor, And Pensions Hearing
PCMA President and CEO Testifying Today on Importance of Preserving Employer Choice and Contracting Flexibility (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released
PCMA Statement On Legislation Introduced By Senate Finance Committee Members
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Finance Committee members: “While we’re currently reviewing
New PCMA Ad Campaign: Reject Big Pharma’s Agenda Designed To Keep Drug Prices High By Undermining Pharmacy Benefits
Congress Must Protect Savings and Choices for Patients and Employers by Rejecting Big Pharma’s Scheme to Eliminate the One Check on Their Pricing Power (Washington,
PCMA Statement on House Oversight Hearing
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement today ahead of the U.S. House Committee on
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
ICYMI: New Survey Finds Overwhelming Majority of Employers Value a Wide Range of Pharmacy Benefit Company Contract Options
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you
Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy